<DOC>
	<DOCNO>NCT02425943</DOCNO>
	<brief_summary>Study design 1. assess long-term safety Sculptra Aesthetic immune-competent subject single regimen correction wrinkle assessment score ( WAS ) 2 4 nasolabial fold ( NLF ) contour deficiency facial wrinkle deep dermal grid pattern ( cross-hatch ) injection technique appropriate . 2. evaluate time onset , duration , severity , relationship Sculptra Aesthetic and/or injection procedure , outcome adverse event course study , Fitzpatrick skin type . 3. evaluate change WAS baseline post-treatment follow-up time point Months 6 , 13 , Years 2 , 3 , 4 , 5 NLFs facial wrinkle . 4. evaluate Investigator/subject global assessment Months 6 , 13 , Years 2 , 3 , 4 , 5 .</brief_summary>
	<brief_title>Sculptra Aesthetic Post-Approval Study</brief_title>
	<detailed_description />
	<mesh_term>Mannitol</mesh_term>
	<criteria>1 . Subjects seek correction shallow deep NLF contour deficiency . Subjects must score ≥2 ≤4 photonumeric wrinkle assessment scale right leave NLFs entry . Subjects may also facial wrinkle ( ie , cheek line , marionette line , chin crease/chin fold ) use Assessment Scale Other Facial Wrinkles deep dermal grid pattern ( crosshatch ) injection technique appropriate . 2 . Subjects must sign statement informed consent ; initial date `` A Patient 's Guide Treatment Sculptra® Aesthetic '' ; sign date `` Health Insurance Portability Accountability Act ( HIPAA ) Authorization '' . 1 . Subjects seek , entry study , correction facial wrinkle Sculptra Aesthetic follow anatomical sites/lines : horizontal forehead line , glabellar frown line , periorbital line , periauricular line , upper lip line , low lip line , corner mouth line and/or horizontal neck fold . 2 . Subjects less 18 great 75 year age . 3 . Subjects score 0 , 1 , 5 photonumeric wrinkle assessment scale either right left NLFs . 4 . Personal history allergic/anaphylactic reaction include hypersensitivity local anesthetic ( eg , lidocaine , etc ) , latex , Sculptra Aesthetic constituent . 5 . History facial skin cancer recurrence facial skin cancer basal cell carcinoma within 5 year . 6 . Known history keloid bleeding/coagulation disorder . 7 . History human immunodeficiency virus , diabetes , connective tissue disorder ( eg , lupus , scleroderma ) , serious systemic disease ( eg , sarcoidosis ) . 8 . Presence surgical nonsurgical scar area treat . 9 . Active inflammatory process infection area treat ( skin eruption cyst , pimple , rash , herpes simplex , herpes zoster , cancerous/precancerous lesion ) , active serious skin disease ( eg , eczema , psoriasis face , severe rosacea , severe acne , etc. ) . 10 . Subjects American Society Anesthesiologists ' Physical Status Classification System Score ≥P3 ( P3 = subject severe systemic disease ) . 11 . Subjects medical condition might require use immunosuppressive ( except oral steroid use less 1 month duration study ) antiinflammatory medication trial ( eg , severe asthma , rheumatoid arthritis , etc ) . 12 . Viral , chemical , active hepatitis within past year . 13 . Planned surgical procedure incision suture area treat course study . 14 . Planned major facial aesthetic procedure/plastic surgery ( eg , rhinoplasty [ without implant ] , facelift , congenital defect repair , etc ) course study . 15 . Subjects plan use exclusionary treatments/medications/ device , describe protocol . 16 . Women pregnant , nurse intend become pregnant duration study woman childbearing potential protected effective contraceptive method birth control and/or unwilling unable test pregnancy . 17 . Subjects unwilling unable give write consent participate investigation unable comply requirement clinical trial protocol . 18 . Subjects receive experimental drug device within previous 3 month prior first treatment . 19 . Subjects know alcohol drug abuser . 20 . Subjects suffer psychological condition , treatment condition , opinion Investigator and/or consult physician ( ) may constitute unwarranted risk may affect subject ' compliance adherence study procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>